☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Atypical Hemolytic Uremic Syndrome
Alexion's Ultomiris (ravulizumab) Receives the CHMP's Positive Opinion for its New Advanced Formulation
September 22, 2020
Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study in Patients with Atypical Hemolytic Uremic Syndrome (AHUS)
January 29, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.